After the Sunshine Act: KOL Fair-Market Value Compensation Trends
June 13, 2013
About the Webinar: Despite the buzz that the Sunshine Act gets, it is no longer the primary driver of FMV compensation trends among biopharmaceutical companies. To be certain, the Sunshine Act will begin to take effect by September of this year. But many drug manufacturers have had their US FMV rates set for several years now. The more significant focus around fair-market value compensation within the industry is now on Western Europe, Asia and even in the Middle East.
About the Speaker: Elio Evangelista has studied medical affairs groups since joining Cutting Edge Information in 2002. He has built his expertise around fair-market value compensation for thought leaders, MSL program operations, continuing medical education support, publications processes and the effects of regulatory change on medical teams. As a leader of Cutting Edge Information’s research group, he has helped CEI clients develop better performance measurement systems, implement strategic recommendations and create more efficient operations.
If you’ve missed out on any of Cutting Edge Information’s live events, you can review the recordings from our webinar archive: